N. Faure

发表

Artificial insemination of husband's sperm.

R. Nachtigall, N. Faure, R. Glass, 1979, Fertility and sterility.

Efficacy of intranasal or subcutaneous luteinizing hormone-releasing hormone agonist inhibition of ovarian function in the treatment of endometriosis.

N. Faure, A. Lemay, R. Maheux, 1988, American journal of obstetrics and gynecology.

Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.

N. Faure, M. Koutsilieris, G. Tolis, 1983, Journal of steroid biochemistry.

Clinical efficacy and safety of low‐dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism

N. Faure, A. Lemay, S. Dodin, 1995, Clinical endocrinology.

Buserelin therapy for prostatic carcinoma

N. Faure, G. Tolis, F. Labrie, 1984 .

Preliminary results on the clinical efficacy and safety of androgen inhibition by an LHRH agonist alone or combined with an antiandrogen in the treatment of prostatic carcinoma

N. Faure, A. Lemay, A. Fazekas, 1983, The Prostate.

Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.

N. Faure, F. Labrie, A. Lemay, 1982, Fertility and sterility.

Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome.

N. Faure, M. Koutsilieris, G. Tolis, 1986, Urology.

Endometrial histology during intermittent intranasal luteinizing hormone-releasing hormone (LH-RH) agonist sequentially combined with an oral progestogen as an antiovulatory contraceptive approach.

N. Faure, A. Lemay, C. Jean, 1987, Fertility and sterility.

Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.

N. Faure, F. Labrie, A. Lemay, 1985, Fertility and sterility.

Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.

N. Faure, A. Lemay, R. Maheux, 1984, Fertility and sterility.

Biological markers in major psychosis and alcoholism: phenotypic and genotypic markers.

N. Faure, A. Lemay, J. Forest, 1984, Journal of psychiatric research.

Sensitivity of pituitary and corpus luteum responses to single intranasal administration of (D-ser[TBU]6-des-gly-NH2(10)) luteinizing hormone-releasing hormone ethylamide (Buserelin) in normal women.

N. Faure, F. Labrie, A. Lemay, 1982, Fertility and sterility.

Gonadotropins and estradiol responses to single intranasal or subcutaneous administration of a luteinizing hormone-releasing hormone agonist in the early follicular phase.

N. Faure, G. Tolis, F. Labrie, 1983, Fertility and sterility.

Gonadotroph and corpus luteum responses to two successive intranasal doses of a luteinizing hormone-releasing hormone agonist at different days after the midcycle luteinizing hormone surge.

N. Faure, F. Labrie, A. Lemay, 1983, Fertility and sterility.

Absence of high affinity dopamine receptor in GH3 cells: a prolactin-secreting clone resistant to the inhibitory action of dopamine.

J. Martial, N. Faure, M. Cronin, 1980, Endocrinology.

Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients.

J. Simard, N. Faure, F. Labrie, 1996, Journal of Clinical Endocrinology and Metabolism.

Effect of somatostatin on thyrotropin, prolactin, growth hormone and insulin responses to thyrotropin releasing hormone and arginine in healthy, hypothyroid and acromegalic subjects.

N. Faure, F. Labrie, J. Dussault, 1977, Canadian Medical Association journal.

OVARIAN SUPPRESSION IN POLYCYSTIC OVARIAN DISEASE DURING 6 MONTH ADMINISTRATION OF A LUTEINIZING HORMONE‐RELEASING HORMONE (LH‐RH) AGONIST

N. Faure, A. Lemay, 1987, Clinical endocrinology.

ACUTE PITUITARY‐OVARIAN RESPONSE DURING CHRONIC LUTEINIZING HORMONE‐RELEASING HORMONE AGONIST ADMINISTRATION IN POLYCYSTIC OVARIAN SYNDROME

N. Faure, A. Lemay, ANDRE LEMAY, 1988, Clinical endocrinology.

Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (Hoe-766) in young normal adult men

N. Faure, F. Labrie, J. Raynaud, 1982, Journal of endocrinological investigation.

Effects of RU16117, an orally active weak oestrogenic compound, in postmenopausal women.

N. Faure, F. Labrie, J. Raynaud, 1980, Maturitas.

Intermittent LHRH Agonist Sequentially Combined with a Progestogen as Antiovulatory Contraception

N. Faure, A. Lemay, 1987 .

Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.

N. Faure, A. Lemay, 1986, The Journal of clinical endocrinology and metabolism.

Inhibition of testicular androgen biosynthesis by chronic administration of a potent LHRH agonist in adult men.

N. Faure, A. Lemay, 1985, Archives of andrology.

Postcoital contraception with intranasal buserelin

N. Faure, F. Labrie, A. Lemay, 1984 .

RU 16117, an orally active estriol-like weak estrogen.

P. Kelly, N. Faure, F. Labrie, 1984, Journal of steroid biochemistry.

Acute and intermittent LHRH agonist dosing as post-coital and anti-ovulatory contraceptive approaches

N. Faure, F. Labrie, A. Lemay, 1985 .

Solid phase extraction and high performance liquid chromatography of tamoxifen and its demethylated metabolites in plasma

N. Faure, J. Guitton, M. Ollagnier, 1998 .

Center for in vitro fertilization, Québec, Canada

N. Faure, A. Lemay, R. Lambert, 1984, Journal of in Vitro Fertilization and Embryo Transfer.

Assessment of ovaries by magnetic resonance imaging in patients presenting with polycystic ovarian syndrome.

N. Faure, A. Lemay, A. Bastide, 1989, Human reproduction.

Ovarian sonographic findings during intermittent intranasal luteinizing hormone-releasing hormone agonist sequentially combined with an oral progestogen as antiovulatory contraceptive approach.

N. Faure, A. Lemay, A. Bastide, 1987, Fertility and sterility.

Reversible down-regulation of pituitary-ovarian function induced by repetitive LH-RH agonist administration as a new approach for treatment and study of endometriosis in the human

N. Faure, A. Lemay, R. Maheux, 1985 .

LH-RH agonist treatment of endometriosis.

N. Faure, A. Lemay, R. Maheux, 1987, Contributions to gynecology and obstetrics.

Decreased responsiveness of GH3 cells to the dopaminergic inhibition of prolactin.

J. Martial, N. Faure, M. Cronin, 1980, Endocrinology.

Hypersensitivity of the human gonadotrophs to the repeated administration of small doses of LH-RH.

N. Faure, G. Olivier, 1978, Hormone research.

ANTERIOR PITUITARY DOPAMINE RECEPTORS AND PROLACTIN SECRETION

N. Faure, M. Cronin, Richard I. Weiner, 1979 .